TrialThe New England journal of medicine2017
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1,333 papers cite itlatest 60 shown
this paperpooled ittrialcites it